India's obesity drug market, despite a significant surge driven by GLP-1 agonists like semaglutide and tirzepatide, is now showing signs of slowing growth. Recent market data indicates that while the GLP-1 segment has reached nearly Rs 2,000 crore, the initial rapid acceleration seen after the introduction of generic versions is beginning to moderate.
GLP-1 Market Sees Initial Boom
The GLP-1 agonist market, led by medications such as Eli Lilly's Mounjaro (tirzepatide) and Novo Nordisk's Ozempic and Wegovy (semaglutide), experienced a substantial increase. According to Pharmarack, the market hit Rs 1,906 crore in the 12 months ending May 2026, marking a 237% jump from the previous year. Tirzepatide alone contributed Rs 1,207 crore, with semaglutide accounting for Rs 589 crore.
The entry of lower-cost generic semaglutide versions by Indian drugmakers played a crucial role in expanding access to these newer diabetes and obesity treatments, fueling this initial growth.
Moderating Growth and Emerging Challenges
Despite the impressive figures, the momentum is slowing. Pharmarack's May 2026 data revealed a deceleration in growth following a strong April, with generic semaglutide products showing signs of stabilization. Industry experts point to several factors contributing to this trend:
Limited New Patient Pool
Sheetal Sapale, Vice President, Commercial at Pharmarack, noted, "Eligible patient population is limited. If the patients who could not afford the innovators have got onboarded on generics, then the new patient pool is limited." Many patients who were awaiting more affordable options may have already started treatment, making it harder to sustain the same growth pace.
Inventory Normalization
The initial launch phase of generic semaglutide saw significant stocking at distributor and stockist levels. J.S. Shinde, President of AIOCD, explained that with the market maturing, "volume uptake has moderated, indicating a transition towards a more sustainable and balanced growth pattern."
Diabetes Focus vs. Obesity Treatment
Salil Kallianpur, a pharmaceutical analyst, highlighted that India's GLP-1 market remains predominantly driven by diabetes treatment, not obesity. "India's GLP-1 market is actually growing fast, projected at 22-34% CAGR. But the obesity indication specifically is the laggard," he stated. Physicians are more accustomed to prescribing GLP-1s for diabetes, and the existing referral infrastructure is largely diabetes-oriented.
Most generic companies, following semaglutide's patent expiry, initially launched their products with Type 2 diabetes indications rather than specific obesity labels. Brands like Dr. Reddy's Obeda and Glenmark's GLIPIQ were approved for diabetes, with only a few, such as Sun Pharma's Noveltreat, carrying a specific obesity indication.
Affordability and Patient Retention Hurdles
For obesity treatment specifically, affordability remains a major barrier. Novo Nordisk's Wegovy, for instance, launched at monthly prices exceeding Rs 24,000 for higher maintenance doses. Even with generic competition, the long-term nature of obesity therapy makes it expensive for most patients, especially since it receives virtually no public reimbursement or private insurance coverage.
Patient retention is also a challenge due to side effects, ongoing costs, and the long-term commitment required. Access to specialists like endocrinologists and obesity experts is concentrated in urban centers, further limiting reach compared to the broader physician network for diabetes management.
Moreover, obesity often faces a perception challenge, with many patients and physicians prioritizing lifestyle modifications before considering drug therapy. This combination of high costs, limited reimbursement, specialist shortages, and treatment dropouts has kept the obesity segment smaller than its potential, despite India's significant burden of metabolic disease.
Rajiv Singhal, General Secretary of AIOCD, confirmed that the broader pharmaceutical market continues to be supported by strong demand in chronic therapies, particularly anti-diabetic medicines, indicating where the primary growth drivers lie.